Clinical Roundup All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds June 18, 2026Vol.52 No.24
Clinical Roundup Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds June 18, 2026Vol.52 No.24
Clinical Roundup Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds June 18, 2026Vol.52 No.24
Clinical Roundup Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds June 18, 2026Vol.52 No.24
Clinical Roundup Antibody may improve treatment response in lung cancer, UTSW-led study finds June 18, 2026Vol.52 No.24
Clinical Roundup Alliance digital tool proves effective at keeping patients engaged in trials June 18, 2026Vol.52 No.24
Clinical Roundup Pediatric cancer exercise guidelines recommend movement during and after treatment June 18, 2026Vol.52 No.24
Clinical Roundup Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds June 12, 2026Vol.52 No.23
